MetaCap

Outlook Therapeutics (OTLK) vs Zura Bio (ZURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zura Bio (ZURA) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 74.4% versus a loss of 79.3%. Outlook Therapeutics is the larger company by market cap ($94.9 million vs $89.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OTLK-79.26%ZURA-74.37%
+103%+2%-99%
Nov 21, 20251 yearNov 20, 2026
OTLK-98.11%ZURA-96.84%
+84%-12%-108%
Mar 20, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OTLK versus ZURA key metrics
MetricOTLKZURA
Share price$0.39$0.9305
Market cap$94.94M$89.63M
1-day change-2.74%-2.30%
YTD return-75.32%-82.24%
1-year return-79.26%-74.37%
5-year return-98.58%—
EPS (TTM)$-0.70$-1.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.41M—
Net income (latest FY)$-62.42M$-68.65M
Gross margin4.05%—
Operating margin-4744.25%—
Net margin-4416.22%—
52-week high$2.54$7.44
52-week low$0.161$0.919
Distance from 52-week high-84.63%-87.49%
Analyst consensusnonestrong_buy
Avg. price target upside+1189.74%+759.75%
Average volume4.60M4.47M
Shares outstanding243.45M96.33M
Employees1740
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Outlook Therapeutics

OTLK stock →

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees

About Zura Bio

ZURA stock →

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

OTLK vs ZURA FAQ

Which is bigger, Outlook Therapeutics or Zura Bio?

Outlook Therapeutics (OTLK) is larger, with a market capitalization of $94.94M compared with $89.63M for Zura Bio (ZURA).

Which stock has performed better over the past year, OTLK or ZURA?

ZURA returned -74.37% over the past 12 months, compared with -79.26% for OTLK (price return, excluding dividends). Past performance does not predict future results.

Are Outlook Therapeutics and Zura Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons